A Novel Prodrug Strategy to Treat Prostate Cancer by Targeting MYC-Driven Nucleotide Biosynthesis

Abstract

Over the research period, the two central hypotheses were investigated thoroughly: testing analogs of ribose-5-phosphate bearing radionuclides for imaging and therapy and testing a prodrug strategy for the delivery and cellular retention of these analogs into diseased prostate cancer cells. Neither could be achieved. The proposed bromine analogs were difficult to synthesize and proved unstable. The prodrug strategy did not liberate the active form necessary for cellular retention. However, through the examination of two goals, a new complimentary approach has been revealed. Furthermore, despite the difficulty with introduction of bromine atoms, fluorine was found to be easily incorporated and stabile, providing a path for the design of a traditional 18F PET imaging tracer for prostate cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2019
Accession Number
AD1098696

Entities

People

  • Matthew Parker

Organizations

  • University of California, San Francisco

Tags

DTIC Thesaurus Topics

  • Anabolism
  • Biomedical Research
  • California
  • Cells
  • Chemical Shifts
  • Chemistry
  • Electronic Mail
  • Fluorine
  • Hypotheses
  • Neoplasms
  • Nucleotides
  • Phosphonic Acids
  • Professional Development
  • Prostate
  • Prostate Cancer
  • Standards
  • Substrates

Fields of Study

  • Chemistry

Readers

  • Medical Imaging.
  • Oncology (Cancer Research).
  • Organic Chemistry